AU2001290523A1 - Gene expression profile for KSHV infection and methods for treating same - Google Patents

Gene expression profile for KSHV infection and methods for treating same

Info

Publication number
AU2001290523A1
AU2001290523A1 AU2001290523A AU9052301A AU2001290523A1 AU 2001290523 A1 AU2001290523 A1 AU 2001290523A1 AU 2001290523 A AU2001290523 A AU 2001290523A AU 9052301 A AU9052301 A AU 9052301A AU 2001290523 A1 AU2001290523 A1 AU 2001290523A1
Authority
AU
Australia
Prior art keywords
kshv
kit
cells
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290523A
Other languages
English (en)
Inventor
Yolanda Bell
Klaus Frueh
Michael Heinrich
Mattias Luukkonen
Ashlee Moses
Jay Nelson
Kenneth Simmen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Oregon Health Science University
Original Assignee
Oregon Health Science University
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Science University, Ortho McNeil Pharmaceutical Inc filed Critical Oregon Health Science University
Publication of AU2001290523A1 publication Critical patent/AU2001290523A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001290523A 2000-08-01 2001-08-01 Gene expression profile for KSHV infection and methods for treating same Abandoned AU2001290523A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22216200P 2000-08-01 2000-08-01
US60222162 2000-08-02
PCT/US2001/024469 WO2002010339A2 (en) 2000-08-01 2001-08-01 Gene expression profile for kshv infection and methods for treating same

Publications (1)

Publication Number Publication Date
AU2001290523A1 true AU2001290523A1 (en) 2002-02-13

Family

ID=22831123

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290523A Abandoned AU2001290523A1 (en) 2000-08-01 2001-08-01 Gene expression profile for KSHV infection and methods for treating same

Country Status (5)

Country Link
US (2) US20030191048A1 (de)
EP (1) EP1307539A4 (de)
JP (1) JP2004520007A (de)
AU (1) AU2001290523A1 (de)
WO (1) WO2002010339A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
AU2003284921A1 (en) * 2002-10-22 2004-05-13 Iconix Pharmaceuticals, Inc. Reticulocyte depletion signatures
WO2004062591A2 (en) * 2003-01-06 2004-07-29 Oregon Health And Science University Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases
EP1524320A1 (de) * 2003-10-15 2005-04-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Schnelle auf DNS-Chip basierende Detektion und Quantifizierung von Verunreinigungen durch Mykoplasmen
CA2546130A1 (en) * 2003-12-04 2005-06-23 Applied Research Systems Ars Holding N.V. Methods for identifying modulators of active kit tyrosine kinase receptor
EP1725295B1 (de) * 2004-01-21 2010-09-15 Emory University Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
ECSP055833A (es) 2004-06-04 2005-09-20 Bioniche Life Sciences Inc Uso de imatinib para tratar trastornos hepáticos e infecciones virales
AU2005270667B2 (en) * 2004-08-13 2011-08-25 Athlomics Pty Ltd Microarray-mediated diagnosis of Herpes Virus infection by monitoring host's differential gene expression upon infection
JP4182227B2 (ja) * 2005-09-09 2008-11-19 国立大学法人 岡山大学 ウイルス潜伏感染の検査方法および検査用キット
US20090105092A1 (en) * 2006-11-28 2009-04-23 The Trustees Of Columbia University In The City Of New York Viral database methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568649A (en) * 1983-02-22 1986-02-04 Immunex Corporation Immediate ligand detection assay
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
US5965352A (en) * 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action

Also Published As

Publication number Publication date
EP1307539A2 (de) 2003-05-07
JP2004520007A (ja) 2004-07-08
WO2002010339A3 (en) 2002-04-04
WO2002010339A2 (en) 2002-02-07
EP1307539A4 (de) 2004-04-28
US20030191048A1 (en) 2003-10-09
US20050100891A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
JP6749431B2 (ja) 心臓血管障害および薬物応答に関連した遺伝子多型、それらの検出方法および用途
JP7175371B2 (ja) スタチンの応答および心血管疾患に関連する遺伝子多型、その検出方法ならびに使用
Wang et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase
CA2612475C (en) Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus
Moses et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells
JP2018057395A (ja) 心筋梗塞に関連する遺伝的多型、その検出方法および使用
US11874283B2 (en) Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
KR20100095564A (ko) 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 및 조성물
CA2924370A1 (en) Mutant calreticulin for the diagnosis of myeloid malignancies
JP5068734B2 (ja) ｋｒｅｍｅｎおよび／またはｗｎｔの異常発現に関連する疾患の診断および治療用組成物
US20190256930A1 (en) Biomarkers for determining responsiveness to lsd1 inhibitors
AU2001290523A1 (en) Gene expression profile for KSHV infection and methods for treating same
Gautheron et al. EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence
Ahmadvand et al. Fgfr2b signaling is essential for the maintenance of the alveolar epithelial type 2 lineage during lung homeostasis in mice
CN116249787A (zh) 用g蛋白偶联受体75(gpr75)抑制剂治疗肥胖症
CA2561901A1 (en) Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5
Koh et al. Oestrogen receptor α genotype, and interactions between vitamin D receptor and transforming growth factor‐β1 genotypes are associated with quantitative calcaneal ultrasound in postmenopausal women
US20030170717A1 (en) Detection of genes regulated by EGF in breast cancer
US6544743B1 (en) Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
WO2004042358A2 (en) HUMAN TYPE II DIABETES GENE-SLIT-3 LOCATED ON CHROMOSOME 5q35
US5863734A (en) Method of treatment for obsessive-compulsive disorder
CN113727732A (zh) 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
CA2837792C (en) Genetic polymorphism in lrp5 associated with liver fibrosis methods of detection and uses thereof
EP1613769B1 (de) Insulin-induziertes gen als therapeutisches ziel bei diabetes
US20090312245A1 (en) SRA binding protein